Two IND clearances this week open clinical development in distinct therapeutic areas. Tr1x Inc. received FDA clearance for TRX‑319 to begin a phase I/IIa study in progressive multiple sclerosis, enabling early‑stage testing of a candidate aimed at slowing neurodegeneration in MS. Separately, Corventum Inc. won IND clearance for CVT‑130, a drug designed to prevent anthracycline‑related cardiotoxicity and enable safer retreatment with chemotherapy. Tr1x plans to initiate trials early next year to evaluate safety and initial efficacy signals; Corventum framed CVT‑130 as a cardioprotective strategy to address cumulative heart damage from anthracyclines. Both INDs reflect regulatory willingness to greenlight therapies addressing high unmet need—neurodegeneration and chemo‑induced cardiac injury. These filings will be watched for trial design choices and biomarker strategies that can accelerate proof‑of‑concept in challenging indications.